Wilmington PharmaTech Company LLC ads

CPHI Milan is almost here! As we approach the weekend before CPHI Worldwide in Milan, the excitement is building! Our team is getting ready to travel to Europe to connect with colleagues, customers, and partners from across the pharmaceutical and biotech industry. We’re looking forward to meaningful conversations around complex API development and manufacturing, HPAPI/ADC capabilities, crystallization and solid-state chemistry, and process development; and, of course, catching up with familiar faces and meeting new ones along the way. Visit Wilmington PharmaTech at Booth 12P22 October 6–8 | Milan, Italy If you’ll be attending CPHI Milan, we’d love to connect! Come see us at Booth 12P22 and let’s talk about how WPT can help manage complexity with confidence. Hui-Yin Harry Li, Mike Shearer, MBA, and Amanda LJ Adams See you in Milan! #CPHIWorldwide #CPHIMilan #CPHI2026 #Pharma #Biotech #CDMO #API #HPAPI #ADC #PharmaceuticalManufacturing #WilmingtonPharmaTech

𝗡𝗲𝘄 𝘄𝗵𝗶𝘁𝗲𝗽𝗮𝗽𝗲𝗿: 𝗧𝗵𝗲 𝗖𝗼𝘀𝘁 𝗼𝗳 𝗗𝗲𝗹𝗮𝘆𝗶𝗻𝗴 𝗦𝗼𝗹𝗶𝗱‑𝗦𝘁𝗮𝘁𝗲 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 The solid state of an API directly shapes its solubility, stability, bioavailability, manufacturability, and overall development feasibility. While alternative forms can often be evaluated easily in early development, once a form is used in toxicology studies, clinical batches, regulatory filings, or IP strategies, it becomes increasingly difficult and costly to change. Ultimately, the challenge is not scientific understanding but timing. Read the full article here: https://lnkd.in/e6D7e2aq/?utm_campaign=WPTBoosts2026&utm_source=linkedin&utm_medium=paid&utm_id=822355204&hsa_acc=516203359&hsa_cam=822355204&hsa_grp=900751664&hsa_ad=1578199394&hsa_net=linkedin&hsa_ver=3 #DrugDevelopment #PharmaceuticalDevelopment #APIDevelopment #SolidStateChemistry #PharmaInnovation #FormulationDevelopment

𝗡𝗲𝘄 𝘄𝗵𝗶𝘁𝗲𝗽𝗮𝗽𝗲𝗿: 𝗗𝗲-𝗥𝗶𝘀𝗸𝗶𝗻𝗴 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗧𝗵𝗿𝗼𝘂𝗴𝗵 𝗔𝘀𝘆𝗺𝗺𝗲𝘁𝗿𝗶𝗰 𝗦𝘆𝗻𝘁𝗵𝗲𝘀𝗶𝘀 From a process chemistry perspective, prioritizing asymmetric synthesis fosters efficient, cost-effective pharmaceutical development. While chromatography serves niche needs, the long-term advantages of asymmetric routes, including scalable purity, reduced waste, and lower COGs, outweigh initial investments, especially for complex chiral molecules. Engaging experts like Wilmington early, pre-IND, maximizes value, reduces costs, and drives innovation. Pharma clients should evaluate asymmetric options first to capitalize on these benefits, acknowledging hybrids where needed for ultimate success. Access whitepaper 👉 https://lnkd.in/eU8DCmzA/?utm_campaign=WPTBoosts2026&utm_source=linkedin&utm_medium=paid&utm_id=822355204&hsa_acc=516203359&hsa_cam=822355204&hsa_grp=899402344&hsa_ad=1563715254&hsa_net=linkedin&hsa_ver=3

We’re heading to ChemOutsourcing! In just a few weeks, the Wilmington PharmaTech team, including Hui-Yin Harry Li, Mike Shearer, MBA, Jonathan Anstett, and Amanda LJ Adams, will be in Boston for ChemOutsourcing 2026! We’re looking forward to connecting with industry partners, meeting new contacts, and discussing how WPT can support your most challenging API and pharmaceutical development needs. Booth 75 | Boston, MA September 15–17 Will you be attending? Let’s connect! We’d love to meet you at the show. #ChemOutsourcing #WilmingtonPharmaTech #CDMO #Pharma #API #DrugDevelopment #Boston

𝗖𝗼𝘀𝘁 𝗶𝘀 𝗻𝗼 𝗹𝗼𝗻𝗴𝗲𝗿 𝘁𝗵𝗲 𝗼𝗻𝗹𝘆 𝗰𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝘄𝗵𝗲𝗻 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗻𝗴 𝗮 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗿 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗽𝗮𝗿𝘁𝗻𝗲𝗿. As geopolitical uncertainty, regulatory complexity and supply chain pressures continue to reshape pharmaceutical outsourcing, companies are taking a much broader view of risk. In a new Pharma's Almanac roundtable, industry leaders discuss how organisations are balancing cost against regulatory compliance, supply security and reputational risk when selecting partners and manufacturing locations. Wilmington PharmaTech Chief Commercial Officer Mike Shearer, MBA shares his perspective on the shift towards regional manufacturing, reshoring and the growing importance of choosing partners that combine cost-effective execution with regulatory compliance, transparency and supply chain resilience. Read the full discussion and Mike’s contribution here 👇 https://lnkd.in/gPWTJ9YZ #CDMO #CRDMO #API #SmallMolecules #PharmaManufacturing #SupplyChain #Reshoring #DrugDevelopment #RiskManagement

𝗡𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝗧𝗼𝗱𝗮𝘆’𝘀 𝗔𝗣𝗜 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 – 𝗔 𝗤&𝗔 𝘄𝗶𝘁𝗵 𝗞𝗲𝗻𝘁 𝗣𝗮𝘆𝗻𝗲 In this Q&A, Kent Payne, Ph.D., Managing Director at Wilmington PharmaTech, discusses the challenges facing today’s small‑molecule developers, from solid‑state risks to route design and scale‑up, and how early, expert intervention can prevent costly delays and keep promising therapies on a viable path to patients. Read the full Q&A here: https://lnkd.in/eEJBmHC3 Get in touch with the team to discuss how Wilmington PharmaTech can support your API development: https://lnkd.in/ev3iDhwK #DrugDevelopment #PharmaceuticalDevelopment #APIDevelopment #PharmaInnovation #FormulationDevelopment